StockData
Biohaven Ltd. logo

Biohaven Ltd. (BHVN) stock

BHVNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 1/30
$12.90−0.34 (-2.57%)

Close on Nov 18, 2026Market cap $1.95BP/E –Yield –

Biohaven operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Biohaven's operating income for the twelve months ending Sep 30, 2026 was -$524.48M. For fiscal 2025 it was -$745.38M. The highest annual figure on record is -$114.51M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$745.38M–
FY2024Dec 31, 2024-$885.11M–
FY2023Dec 31, 2023-$436.05M–
FY2022Dec 31, 2022-$567.93M–
FY2021Dec 31, 2021-$218.90M–
FY2020Dec 31, 2020-$114.51M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$126.42M–
Q2 FY2026Jun 30, 2026-$124.90M–
Q1 FY2026Mar 31, 2026-$130.43M–
Q4 FY2025Dec 31, 2025-$142.73M–
Q3 FY2025Sep 30, 2025-$169.38M–
Q2 FY2025Jun 30, 2025-$211.70M–
Q1 FY2025Mar 31, 2025-$221.56M–
Q4 FY2024Dec 31, 2024-$189.93M–
Q3 FY2024Sep 30, 2024-$178.17M–
Q2 FY2024Jun 30, 2024-$333.77M–
Q1 FY2024Mar 31, 2024-$183.24M–
Q4 FY2023Dec 31, 2023-$153.71M–
Q3 FY2023Sep 30, 2023-$110.55M–
Q2 FY2023Jun 30, 2023-$94.01M–
Q1 FY2023Mar 31, 2023-$77.78M–
Q4 FY2022Dec 31, 2022-$213.41M–
Q3 FY2022Sep 30, 2022-$67.64M–
Q2 FY2022Jun 30, 2022-$197.11M–
Q1 FY2022Mar 31, 2022-$89.77M–
Q4 FY2021Dec 31, 2021-$50.88M–
Q3 FY2021Sep 30, 2021-$55.49M–

More Biohaven figures

See a number that looks wrong?